TrueWealth LLC’s Blueprint Medicines BPMC Stock Holding History

TrueWealth LLC’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-42	Closed	-$3K	–	735
2018 Q3	$3K	Buy	+42	New	+$2.92K	﹤0.01%	668

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

TrueWealth LLC's BPMC Position: Q4 2018 in Review

TrueWealth LLC sold out of Blueprint Medicines (BPMC) in Q4 2018, closing a stake of 42 shares — an estimated $3K sold.

TrueWealth LLC first reported a position in BPMC in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 162 funds tracked by Wall St. Rank hold BPMC as of Q4 2018.

TrueWealth LLC reported no remaining Blueprint Medicines position as of Q4 2018 after selling out during the quarter.
TrueWealth LLC sold 42 Blueprint Medicines shares in Q4 2018, an estimated $3K.
TrueWealth LLC first reported a position in Blueprint Medicines in Q3 2018 and held it in 1 quarter.
TrueWealth LLC's Blueprint Medicines position peaked at $3K in Q3 2018.
162 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2018.

Based on TrueWealth LLC's 13F filing for Q4 2018, filed 18 Jan 2019.